RUNX2 and prostate cancer: RUNX2 also functions as a chaperone for the recruitment of G9a to endogenous RUNX2 binding sites on the chromatin, activating RUNX2 target genes MMP9, CST7, SDF1, and CSF, which are known to drive EMT and metastasis in breast and prostate cancers [108].